{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:46:28Z","timestamp":1792791988901,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Nutrition"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tjnut.2025.07.004","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T23:47:35Z","timestamp":1752623255000},"page":"2811-2824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combination Supplement Therapy: A New Frontier in Treatment of Neurodegenerative Diseases"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-8637","authenticated-orcid":false,"given":"Alexander","family":"Shtilbans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.tjnut.2025.07.004_bib1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"10.1016\/j.tjnut.2025.07.004_bib2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/jnnp-2014-308350","article-title":"Neuronal network disintegration: common pathways linking neurodegenerative diseases","volume":"87","author":"Ahmed","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"11","key":"10.1016\/j.tjnut.2025.07.004_bib3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrneurol.2017.147","article-title":"A systemic view of Alzheimer disease\u2014insights from amyloid-beta metabolism beyond the brain","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"5688","key":"10.1016\/j.tjnut.2025.07.004_bib4","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuron.2009.01.033","article-title":"Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons","volume":"62","author":"Mosharov","year":"2009","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.tjnut.2025.07.004_bib6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.cell.2013.11.009","article-title":"Isogenic human iPSC Parkinson\u2019s model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription","volume":"155","author":"Ryan","year":"2013","journal-title":"Cell."},{"key":"10.1016\/j.tjnut.2025.07.004_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.09.012","article-title":"Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson\u2019s disease","volume":"155","author":"Zucca","year":"2017","journal-title":"Prog. Neurobiol."},{"issue":"7","key":"10.1016\/j.tjnut.2025.07.004_bib8","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/brain\/awt134","article-title":"Parkinson\u2019s disease is associated with altered expression of CaV1 channels and calcium-binding proteins","volume":"136","author":"Hurley","year":"2013","journal-title":"Brain"},{"issue":"B","key":"10.1016\/j.tjnut.2025.07.004_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","article-title":"Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease","volume":"109","author":"Rocha","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tjnut.2025.07.004_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1492028","article-title":"Combination of tauroursodeoxycholic acid, co-enzyme Q10 and creatine demonstrates additive neuroprotective effects in in-vitro models of Parkinson\u2019s disease","volume":"18","author":"Shtilbans","year":"2024","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.tjnut.2025.07.004_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson\u2019s disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.tjnut.2025.07.004_bib12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.tjnut.2025.07.004_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","article-title":"N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases","volume":"36","author":"Holmay","year":"2013","journal-title":"Clin. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.tjnut.2025.07.004_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157602","article-title":"N-acetyl cysteine may support dopamine neurons in Parkinson\u2019s disease: preliminary clinical and cell line data","volume":"11","author":"Monti","year":"2016","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ene.12664","article-title":"Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis","volume":"23","author":"Elia","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.tjnut.2025.07.004_bib16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.tjnut.2025.07.004_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.tjnut.2025.07.004_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2174\/1871527317666180720162029","article-title":"Amyotrophic lateral sclerosis and oxidative stress: a double-blind therapeutic trial after curcumin supplementation","volume":"17","author":"Chico","year":"2018","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.tjnut.2025.07.004_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.freeradbiomed.2022.11.003","article-title":"Taurine attenuates neuronal ferroptosis by regulating GABAB\/AKT\/GSK3\u03b2\/\u03b2-catenin pathway after subarachnoid hemorrhage","volume":"193","author":"Liu","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.tjnut.2025.07.004_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2016.11.011","article-title":"Neuroprotective influence of taurine on fluoride-induced biochemical and behavioral deficits in rats","volume":"261","author":"Adedara","year":"2017","journal-title":"Chem. Biol. Interact."},{"issue":"8","key":"10.1016\/j.tjnut.2025.07.004_bib21","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.neuropharm.2005.06.015","article-title":"Activation of GABAA receptors by taurine and muscimol blocks the neurotoxicity of \u03b2-amyloid in rat hippocampal and cortical neurons","volume":"49","author":"Paula-Lima","year":"2005","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib22","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1038\/srep07467","article-title":"Taurine in drinking water recovers learning and memory in the adult APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"4","author":"Kim","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tjnut.2025.07.004_bib23","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s10072-013-1444-3","article-title":"Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer\u2019s type (SDAT) caused by intracerebroventricular streptozotocin in rats","volume":"34","author":"Javed","year":"2013","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.tjnut.2025.07.004_bib24","series-title":"Taurine 10. Advances in Experimental Medicine and Biology","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-024-1079-2_21","article-title":"Taurine directly binds to oligomeric amyloid-\u03b2 and recovers cognitive deficits in Alzheimer model mice","author":"Jang","year":"2017"},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1423-0127-21-51","article-title":"Taurine improves the spatial learning and memory ability impaired by sub-chronic manganese exposure","volume":"21","author":"Lu","year":"2014","journal-title":"J. Biomed. Sci."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3126\/kumj.v19i2.49646","article-title":"Taurine can decrease phosphorylated tau protein levels in Alzheimer\u2019s model rats\u2019 brains","volume":"19","author":"Jahanshahi","year":"2021","journal-title":"Kathmandu Univ. Med. J."},{"issue":"4","key":"10.1016\/j.tjnut.2025.07.004_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41419-018-0468-2","article-title":"Taurine protects dopaminergic neurons in a mouse Parkinson\u2019s disease model through inhibition of microglial M1 polarization","volume":"9","author":"Che","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.tjnut.2025.07.004_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00726-018-2547-1","article-title":"Taurine protects noradrenergic locus coeruleus neurons in a mouse Parkinson\u2019s disease model by inhibiting microglial M1 polarization","volume":"50","author":"Hou","year":"2018","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00726-021-03104-6","article-title":"Taurine protects dopaminergic neurons in paraquat-induced Parkinson\u2019s disease mouse model through PI3K\/Akt signaling pathways","volume":"54","author":"Wang","year":"2022","journal-title":"Amino Acids"},{"key":"10.1016\/j.tjnut.2025.07.004_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neuro.2021.01.002","article-title":"Taurine improves neuron injuries and cognitive impairment in a mouse Parkinson\u2019s disease model through inhibition of microglial activation","volume":"83","author":"Wang","year":"2021","journal-title":"Neurotoxicology"},{"issue":"11","key":"10.1016\/j.tjnut.2025.07.004_bib31","first-page":"801","article-title":"Protective effects of taurine on neurons and microglia in Parkinson\u2019s disease-like mouse model induced by paraquat","volume":"38","author":"Tian","year":"2020","journal-title":"Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi"},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.pbb.2005.10.018","article-title":"Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington\u2019s disease phenotype","volume":"82","author":"Tadros","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tjnut.2025.07.004_bib33","series-title":"Taurine 10. Advances in Experimental Medicine and Biology","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-024-1079-2_70","article-title":"Taurine protects glutamate neurotoxicity in motor neuron cells","author":"Lee","year":"2017"},{"key":"10.1016\/j.tjnut.2025.07.004_bib34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12035-012-8371-9","article-title":"Expression of taurine transporter (TauT) is modulated by heat shock factor 1 (HSF1) in motor neurons of ALS","volume":"47","author":"Jung","year":"2013","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4161\/pri.28938","article-title":"The therapeutic potential of chemical chaperones in protein folding diseases","volume":"8","author":"Cortez","year":"2014","journal-title":"Prion"},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7453\/gahmj.2014.017","article-title":"The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases","volume":"3","author":"Vang","year":"2014","journal-title":"Glob. Adv. Health Med."},{"issue":"10","key":"10.1016\/j.tjnut.2025.07.004_bib37","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"issue":"15","key":"10.1016\/j.tjnut.2025.07.004_bib38","doi-asserted-by":"crossref","first-page":"7660","DOI":"10.1128\/JVI.01165-15","article-title":"Bile acids reduce prion conversion, reduce neuronal loss, and prolong male survival in models of prion disease","volume":"89","author":"Cortez","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.tjnut.2025.07.004_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nbd.2012.09.003","article-title":"Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP\/PS1 mice","volume":"50","author":"Lo","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12035-012-8256-y","article-title":"TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-beta deposition in APP\/PS1 mice","volume":"45","author":"Nunes","year":"2012","journal-title":"Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.tjnut.2025.07.004_bib41","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/cells8121471","article-title":"Tauroursodeoxycholate-bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives","volume":"8","author":"Kusaczuk","year":"2019","journal-title":"Cells"},{"issue":"9\u201312","key":"10.1016\/j.tjnut.2025.07.004_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2119\/2003-00042.Rodrigues","article-title":"Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway","volume":"9","author":"Sola","year":"2003","journal-title":"Mol. Med."},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3727\/096020198389960","article-title":"Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson\u2019s disease","volume":"11","author":"Duan","year":"2002","journal-title":"Cell. Transplant."},{"issue":"4\u20136","key":"10.1016\/j.tjnut.2025.07.004_bib44","first-page":"659","article-title":"Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression","volume":"26","author":"Weihe","year":"2006","journal-title":"Cell. Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12035-012-8295-4","article-title":"Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson\u2019s disease","volume":"46","author":"Castro-Caldas","year":"2012","journal-title":"Mol. Neurobiol."},{"issue":"9","key":"10.1016\/j.tjnut.2025.07.004_bib46","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.bbadis.2017.06.004","article-title":"Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease","volume":"1863","author":"Rosa","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"8","key":"10.1016\/j.tjnut.2025.07.004_bib47","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/jcp.25742","article-title":"TUDCA: an agonist of the bile acid receptor GPBAR1\/TGR5 with anti-inflammatory effects in microglial cells","volume":"232","author":"Yanguas-Casas","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tjnut.2025.07.004_bib48","series-title":"Compositions for improving cell viability and methods of use thereof patent, WO 2014\/158547 A1","author":"Cohen","year":"2014"},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/exnr.2001.7755","article-title":"A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington\u2019s disease","volume":"171","author":"Keene","year":"2001","journal-title":"Exp. Neurol."},{"issue":"16","key":"10.1016\/j.tjnut.2025.07.004_bib50","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1073\/pnas.162362299","article-title":"Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington\u2019s disease","volume":"99","author":"Keene","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/biomedicines9020173","article-title":"Curcumin as scaffold for drug discovery against neurodegenerative diseases","volume":"9","author":"Lo Cascio","year":"2021","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.tjnut.2025.07.004_bib52","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid \u03b2 oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/acschemneuro.5b00214","article-title":"Curcumin attenuates amyloid-\u03b2 aggregate toxicity and modulates amyloid-\u03b2 aggregation pathway","volume":"7","author":"Thapa","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib54","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3233\/JAD-170351","article-title":"Curcumin inhibits tau aggregation and disintegrates preformed tau filaments in vitro","volume":"60","author":"Rane","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.tjnut.2025.07.004_bib55","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00418-016-1464-1","article-title":"A comparative study of dietary curcumin, nanocurcumin, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5\u00d7-familial Alzheimer\u2019s disease mice","volume":"146","author":"Maiti","year":"2016","journal-title":"Histochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-2006-10101","article-title":"Curcuminoids enhance amyloid-\u03b2 uptake by macrophages of Alzheimer\u2019s disease patients","volume":"10","author":"Zhang","year":"2006","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.tjnut.2025.07.004_bib57","first-page":"3846","article-title":"[Neuroprotective effect of curcumin to A\u03b2 of double transgenic mice with Alzheimer\u2019s disease]","volume":"39","author":"Feng","year":"2014","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"4","key":"10.1016\/j.tjnut.2025.07.004_bib58","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3233\/JAD-2012-120688","article-title":"Curcumin-mediated neuroprotection against amyloid-\u03b2-induced mitochondrial dysfunction involves the inhibition of GSK-3\u03b2","volume":"32","author":"Huang","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.tjnut.2025.07.004_bib59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fphar.2016.00261","article-title":"Curcumin attenuates beta-amyloid-induced neuroinflammation via activation of peroxisome proliferator-activated receptor-gamma function in a rat model of Alzheimer\u2019s disease","volume":"7","author":"Liu","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tjnut.2025.07.004_bib60","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00401-007-0332-4","article-title":"Curcumin inhibits aggregation of \u03b1-synuclein","volume":"115","author":"Pandey","year":"2008","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-11-57","article-title":"Curcumin reduces \u03b1-synuclein induced cytotoxicity in Parkinson\u2019s disease cell model","volume":"11","author":"Wang","year":"2010","journal-title":"BMC Neurosci"},{"issue":"5","key":"10.1016\/j.tjnut.2025.07.004_bib62","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.phrs.2011.01.004","article-title":"Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for parkinsonism","volume":"63","author":"Liu","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tjnut.2025.07.004_bib63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12264-012-1238-2","article-title":"Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson\u2019s disease","volume":"28","author":"Du","year":"2012","journal-title":"Neurosci. Bull."},{"issue":"7","key":"10.1016\/j.tjnut.2025.07.004_bib64","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.3390\/ijms13079097","article-title":"Curcumin inhibits glutamate release from rat prefrontal nerve endings by affecting vesicle mobilization","volume":"13","author":"Lin","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.taap.2015.03.010","article-title":"Curcumin attenuates glutamate neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP\/NLRP3 inflammasome activation in a manner dependent on AMPK","volume":"286","author":"Li","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tjnut.2025.07.004_bib66","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11481-012-9431-7","article-title":"Curcumin ameliorates the neurodegenerative pathology in A53T \u03b1-synuclein cell model of Parkinson\u2019s disease through the downregulation of mTOR\/p70S6K signaling and the recovery of macroautophagy","volume":"8","author":"Jiang","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-7-12","article-title":"Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington\u2019s disease","volume":"7","author":"Hickey","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.tjnut.2025.07.004_bib68","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12017-013-8261-y","article-title":"Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington\u2019s disease","volume":"16","author":"Sandhir","year":"2014","journal-title":"Neuromol. Med."},{"issue":"7\u20138","key":"10.1016\/j.tjnut.2025.07.004_bib69","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/21678421.2021.2012699","article-title":"Therapeutic effect of a novel curcumin derivative GT863 on a mouse model of amyotrophic lateral sclerosis","volume":"23","author":"Kato","year":"2022","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"issue":"Suppl 4","key":"10.1016\/j.tjnut.2025.07.004_bib70","article-title":"Coenzyme Q10 effects in neurological diseases","volume":"70","author":"Rauchova","year":"2021","journal-title":"Physiol. Res."},{"key":"10.1016\/j.tjnut.2025.07.004_bib71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12031-009-9297-1","article-title":"Coenzyme Q10 reduces \u03b2-amyloid plaque in an APP\/PS1 transgenic mouse model of Alzheimer\u2019s disease","volume":"41","author":"Yang","year":"2010","journal-title":"J. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib72","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110209","article-title":"Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer\u2019s disease","volume":"27","author":"Dumont","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.tjnut.2025.07.004_bib73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainresbull.2019.01.025","article-title":"Investigation of protective effects of coenzyme Q10 on impaired synaptic plasticity in a male rat model of Alzheimer\u2019s disease","volume":"147","author":"Komaki","year":"2019","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbr.2006.03.009","article-title":"Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats","volume":"171","author":"Ishrat","year":"2006","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/JAD-170275","article-title":"Ubisol-Q 10 (a nanomicellar water-soluble formulation of CoQ 10) treatment inhibits Alzheimer-type behavioral and pathological symptoms in a double transgenic mouse (TgAPEswe, PSEN1dE9) model of Alzheimer\u2019s disease","volume":"61","author":"Muthukumaran","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.tjnut.2025.07.004_bib76","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1471-4159.2007.05097.x","article-title":"Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism","volume":"104","author":"Cleren","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tjnut.2025.07.004_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-10-88","article-title":"Paraquat induces oxidative stress, neuronal loss in substantia nigra region and Parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q 10","volume":"10","author":"Somayajulu-Ni\u0163u","year":"2009","journal-title":"BMC Neurosci"},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FBP.0000000000000342","article-title":"Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson\u2019s disease in experimental animals","volume":"29","author":"Attia","year":"2018","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib79","doi-asserted-by":"crossref","first-page":"9572","DOI":"10.1038\/s41598-020-66493-w","article-title":"Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson\u2019s disease rat model","volume":"10","author":"Park","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.tjnut.2025.07.004_bib80","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s diseases","volume":"109","author":"Yang","year":"2009","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.mcn.2011.10.007","article-title":"Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington\u2019s disease","volume":"49","author":"Hickey","year":"2012","journal-title":"Mol. Cell. Neurosci."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib82","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410410206","article-title":"Energy metabolism defects in Huntington\u2019s disease and effects of coenzyme Q10","volume":"41","author":"Koroshetz","year":"1997","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.tjnut.2025.07.004_bib83","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib84","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington\u2019s disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib85","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/nu13020586","article-title":"Creatine supplementation and brain health","volume":"13","author":"Roschel","year":"2021","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.tjnut.2025.07.004_bib86","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.3390\/nu12113589","article-title":"Sex-specific effects of chronic creatine supplementation on hippocampal-mediated spatial cognition in the 3xTg mouse model of Alzheimer\u2019s disease","volume":"12","author":"Snow","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.tjnut.2025.07.004_bib87","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1046\/j.1471-4159.2000.0741968.x","article-title":"Protective effect of the energy precursor creatine against toxicity of glutamate and \u03b2-amyloid in rat hippocampal neurons","volume":"74","author":"Brewer","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tjnut.2025.07.004_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdnut.2023.102011","article-title":"Creatine as a therapeutic target in Alzheimer\u2019s disease","volume":"7","author":"Smith","year":"2023","journal-title":"Curr. Dev. Nutr."},{"issue":"8","key":"10.1016\/j.tjnut.2025.07.004_bib89","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.3390\/nu13082758","article-title":"Creatine supplementation upregulates mTORC1 signaling and markers of synaptic plasticity in the dentate gyrus while ameliorating LPS-induced cognitive impairment in female rats","volume":"13","author":"Mao","year":"2021","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.tjnut.2025.07.004_bib90","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/13825580600788100","article-title":"Creatine supplementation and cognitive performance in elderly individuals","volume":"14","author":"McMorris","year":"2007","journal-title":"Neuropsychol. Dev. Cogn. B. Aging Neuropsychol. Cogn."},{"issue":"3\u20134","key":"10.1016\/j.tjnut.2025.07.004_bib91","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000377676","article-title":"The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson\u2019s disease","volume":"73","author":"Li","year":"2015","journal-title":"Eur. Neurol."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib92","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1545968306293449","article-title":"Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial, Neurorehabil","volume":"21","author":"Hass","year":"2007","journal-title":"Neural Repair"},{"issue":"6","key":"10.1016\/j.tjnut.2025.07.004_bib93","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jama.2015.120","article-title":"Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial","volume":"313","author":"Kieburtz","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.tjnut.2025.07.004_bib94","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1385\/JMN:21:3:191","article-title":"Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson\u2019s disease","volume":"21","author":"Klivenyi","year":"2003","journal-title":"J. Mol. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.tjnut.2025.07.004_bib95","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-510X(01)00611-6","article-title":"Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results","volume":"191","author":"Mazzini","year":"2001","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib96","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/6568","article-title":"Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis","volume":"5","author":"Klivenyi","year":"1999","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib97","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1471-4159.2001.00188.x","article-title":"Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation","volume":"77","author":"Andreassen","year":"2001","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.tjnut.2025.07.004_bib98","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","article-title":"Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington\u2019s disease transgenic mice","volume":"85","author":"Dedeoglu","year":"2003","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib99","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","article-title":"Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington\u2019s disease","volume":"8","author":"Andreassen","year":"2001","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"10.1016\/j.tjnut.2025.07.004_bib100","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington\u2019s disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib101","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/brb3.208","article-title":"N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities","volume":"4","author":"Bavarsad Shahripour","year":"2014","journal-title":"Brain Behav"},{"key":"10.1016\/j.tjnut.2025.07.004_bib102","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2469486","article-title":"N-acetylcysteine for the treatment of psychiatric disorders: a review of current evidence","volume":"2018","author":"Ooi","year":"2018","journal-title":"BioMed Res. Int."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainres.2006.06.042","article-title":"Protective effect of N-acetyl-L-cysteine on amyloid \u03b2-peptide-induced learning and memory deficits in mice","volume":"1109","author":"Fu","year":"2006","journal-title":"Brain Res"},{"issue":"12","key":"10.1016\/j.tjnut.2025.07.004_bib104","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1002\/jnr.22422","article-title":"Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP\/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment","volume":"88","author":"Huang","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.tjnut.2025.07.004_bib105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1010065103073","article-title":"N-Acetyl-L-Cystein downregulates \u03b2-amyloid precursor protein gene transcription in human neuroblastoma cells","volume":"2","author":"Studer","year":"2001","journal-title":"Biogerontology"},{"key":"10.1016\/j.tjnut.2025.07.004_bib106","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cbi.2017.05.008","article-title":"N-acetylcysteine treatment attenuates the cognitive impairment and synaptic plasticity loss induced by streptozotocin","volume":"272","author":"da Costa","year":"2017","journal-title":"Chem. Biol. Interact."},{"issue":"4","key":"10.1016\/j.tjnut.2025.07.004_bib107","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3233\/JAD-151098","article-title":"Maintenance of cognitive performance and mood for individuals with Alzheimer\u2019s disease following consumption of a nutraceutical formulation: a one-year, open-label study","volume":"51","author":"Remington","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.tjnut.2025.07.004_bib108","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JAD-142499","article-title":"A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer\u2019s disease","volume":"45","author":"Remington","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"8","key":"10.1016\/j.tjnut.2025.07.004_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012333","article-title":"Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in \u03b1-synuclein overexpressing mice","volume":"5","author":"Clark","year":"2010","journal-title":"PLOS One"},{"issue":"6","key":"10.1016\/j.tjnut.2025.07.004_bib110","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/10715760802158430","article-title":"Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson\u2019s disease","volume":"42","author":"Bagh","year":"2008","journal-title":"Free Radic. Res."},{"issue":"11","key":"10.1016\/j.tjnut.2025.07.004_bib111","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1097\/00001756-200008030-00029","article-title":"N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis","volume":"11","author":"Andreassen","year":"2000","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib112","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0969-9961(03)00043-3","article-title":"Mitochondrial dysfunction due to mutant copper\/zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine","volume":"13","author":"Beretta","year":"2003","journal-title":"Neurobiol. Dis."},{"issue":"23","key":"10.1016\/j.tjnut.2025.07.004_bib113","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1523\/JNEUROSCI.16-23-07574.1996","article-title":"Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine","volume":"16","author":"Henderson","year":"1996","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.tjnut.2025.07.004_bib114","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.131","article-title":"N-acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6\/1 mouse model of Huntington\u2019s disease","volume":"5","author":"Wright","year":"2015","journal-title":"Transl. Psychiatry."},{"issue":"14","key":"10.1016\/j.tjnut.2025.07.004_bib115","first-page":"2923","article-title":"N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington\u2019s disease","volume":"25","author":"Wright","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.tjnut.2025.07.004_bib116","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000334273","article-title":"N-acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington\u2019s disease","volume":"9","author":"Sandhir","year":"2012","journal-title":"Neurodegener. Dis."},{"issue":"8","key":"10.1016\/j.tjnut.2025.07.004_bib117","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/iub.2595","article-title":"Central nervous system organoids for modeling neurodegenerative diseases","volume":"74","author":"Hou","year":"2022","journal-title":"IUBMB Life."}],"container-title":["The Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022316625004274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022316625004274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:17:32Z","timestamp":1774268252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022316625004274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":117,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0022316625004274"],"URL":"https:\/\/doi.org\/10.1016\/j.tjnut.2025.07.004","relation":{},"ISSN":["0022-3166"],"issn-type":[{"value":"0022-3166","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Supplement Therapy: A New Frontier in Treatment of Neurodegenerative Diseases","name":"articletitle","label":"Article Title"},{"value":"The Journal of Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjnut.2025.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Nutrition. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}